| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 28,988 | 24,087 | ||
| General and administrative | 5,117 | 4,342 | ||
| Total operating expenses | 34,105 | 28,429 | ||
| Loss from operations | -34,105 | -28,429 | ||
| Interest income | 3,832 | 3,857 | ||
| Interest expense | - | 0 | ||
| Other expense, net | 4 | 2 | ||
| Total other income (expense), net | 3,828 | 3,855 | ||
| Net loss | -30,277 | -24,574 | ||
| Net change in unrealized gains (losses) on marketable securities | 212 | -21 | ||
| Comprehensive loss | -30,065 | -24,595 | ||
| Net loss per share attributable to stockholders, basic (in dollars per share) | - | -0.46 | ||
| Net loss per share attributable to stockholders, diluted (in dollars per share) | - | -0.46 | ||
| Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in shares) | - | 42,095,951 | ||
| Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in shares) | - | 42,095,951 | ||
| Net loss per share attributable to stockholders, basic (in dollars per share) | -0.55 | - | ||
| Net loss per share attributable to stockholders, diluted (in dollars per share) | -0.55 | - | ||
| Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in shares) | 44,067,059 | - | ||
| Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in shares) | 44,067,059 | - | ||
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)